Table 1.
Characteristics of the included studies
| Reference | Study design | Study site | Study population | Study drug | Control group | No. in study group | No. in control group |
|---|---|---|---|---|---|---|---|
| Abbaspour Kasgari et al., 2020 [9] | Open-label RCT | 1 centre in Iran | Hospitalised patients with moderate COVID-19 | SOF (400 mg)/DCV (60 mg) plus RBV (1200 mg) | HCQ and LPV/r with or without RBV | 24 | 24 |
| Abbass et al., 2021 [16] | Open-label RCT | 4 centres in Egypt | Moderate to severe COVID-19 | SOF (400 mg)/DCV (60 mg) or SOF (400 mg)/RDV 200 mg | Standard of care | SOF/DCV: 40; SOF/RDV: 40 | 40 |
| El-Bendary et al., 2022 [10] | Open-label RCT | 3 centres in Egypt | Adult patients with COVID-19 and pneumonia on chest CT | SOF (400 mg)/DCV (60 mg) | HCQ | 96 | 78 |
| Eslami et al, 2020 [11] | Open-label parallel trial | 1 centre in Iran | Hospitalised patients with severe COVID-19 | SOF (400 mg)/DCV (60 mg) | RBV | 35 | 27 |
| Khalili et al., 2020 [13] | Open-label RCT | 1 centre in Iran | Hospitalised patients with mild or moderate COVID-19 | SOF (400 mg)/LED (90 mg) | HCQ and ATV/r | 42 | 40 |
| Roozbeh et al., 2021 [12] | Double-blind, parallel-group, active-controlled RCT | 1 centre in Iran | Outpatients with mild COVID-19 | SOF (400 mg)/DCV (60 mg) plus HCQ | HCQ | 27 | 28 |
| Sadeghi et al., 2020 [15] | Open-label RCT | 2 centres in Iran | Hospitalised patients with moderate or severe COVID-19 | SOF (400 mg)/DCV (60 mg) | HCQ and LPV/r | 33 | 33 |
| Sayad et al., 2021 [14] | Open-label RCT | 1 centre in Iran | Hospitalised patients with moderate or severe COVID-19 | SOF (400 mg)/VEL (100 mg) | HCQ and LPV/r | 40 | 40 |
RCT, randomised controlled trial; COVID-19, coronavirus disease 2019; SOF, sofosbuvir; DCV, daclatasvir; RBV, ribavirin; HCQ, hydroxychloroquine; LPV/r, lopinavir/ritonavir; RDV, ravidasvir; CT, computed tomography; LED, ledipasvir; ATV/r, atazanavir/ritonavir; VEL, velpatasvir.